Drug intelligence / Profile preview

TL-102

Development stage: Preclinical
Lead developer: Spirovant Sciences
Modality: Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Inhalation

Overview

TL-102 is a lentiviral-based gene therapy product candidate developed by Talee Bio (now Spirovant Sciences) for the treatment of cystic fibrosis. It is designed as a mutation-agnostic therapy to accelerate the development of treatments for all cystic fibrosis patients, particularly those with limited or no other treatment options, by overcoming historical challenges in gene therapy delivery to the lung. The therapy is intended to address the underlying cause of the disease.

Targets

CFTR (Cystic fibrosis transmembrane conductance regulator)

Beyond the preview

Go deeper on TL-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TL-102.

Explore the full profile